4/25
07:58 am
acrs
Cryopyrin-Associated Periodic Syndrome Drug Pipeline Report 2024: Therapeutic Developments for Zydus Cadila, Novartis, Inflazome, Roche, Aclaris Therapeutics, and Mabpharm [Yahoo! Finance]
Medium
Report
Cryopyrin-Associated Periodic Syndrome Drug Pipeline Report 2024: Therapeutic Developments for Zydus Cadila, Novartis, Inflazome, Roche, Aclaris Therapeutics, and Mabpharm [Yahoo! Finance]
4/23
08:12 am
acrs
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer [Yahoo! Finance]
Low
Report
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer [Yahoo! Finance]
4/23
08:00 am
acrs
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
Low
Report
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
4/11
10:26 am
acrs
Favourable Signals For Aclaris Therapeutics: Numerous Insiders Acquired Stock [Yahoo! Finance]
Medium
Report
Favourable Signals For Aclaris Therapeutics: Numerous Insiders Acquired Stock [Yahoo! Finance]
4/5
11:59 am
acrs
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year? [Yahoo! Finance]
Low
Report
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year? [Yahoo! Finance]
4/2
02:05 am
acrs
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
3/25
11:37 pm
acrs
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
3/8
02:04 am
acrs
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
2/27/2024
07:00 am
ACRS
aclaris therapeutics, inc.
BEAT
Report
-4.0%
aclaris therapeutics, inc.
8/7/2023
07:00 am
ACRS
aclaris therapeutics, inc.
BEAT
Report
-8.6%
aclaris therapeutics, inc.
5/8/2023
07:00 am
ACRS
aclaris therapeutics, inc.
BEAT
Report
-9.7%
aclaris therapeutics, inc.
4/25
07:03 am
acrs
Form ARS Aclaris Therapeutics, For: Dec 31
Low
Report
Form ARS Aclaris Therapeutics, For: Dec 31
4/25
07:02 am
acrs
Form DEFA14A Aclaris Therapeutics,
Low
Report
Form DEFA14A Aclaris Therapeutics,
4/25
07:01 am
acrs
Form DEF 14A Aclaris Therapeutics, For: Jun 06
Low
Report
Form DEF 14A Aclaris Therapeutics, For: Jun 06
4/3
05:01 pm
acrs
Form 4 Aclaris Therapeutics, For: Apr 01 Filed by: Walker Neal
Low
Report
Form 4 Aclaris Therapeutics, For: Apr 01 Filed by: Walker Neal
3/19
04:32 pm
acrs
Form 8-K Aclaris Therapeutics, For: Mar 14
Low
Report
Form 8-K Aclaris Therapeutics, For: Mar 14
3/5
05:08 pm
acrs
Form 4 Aclaris Therapeutics, For: Mar 01 Filed by: Walker Neal
High
Report
Form 4 Aclaris Therapeutics, For: Mar 01 Filed by: Walker Neal
3/5
05:05 pm
acrs
Form 4 Aclaris Therapeutics, For: Mar 01 Filed by: Monahan Joseph
Medium
Report
Form 4 Aclaris Therapeutics, For: Mar 01 Filed by: Monahan Joseph
3/5
05:02 pm
acrs
Form 4 Aclaris Therapeutics, For: Mar 01 Filed by: Balthaser Kevin
High
Report
Form 4 Aclaris Therapeutics, For: Mar 01 Filed by: Balthaser Kevin
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd lot
Avg. bid-ask spread
Avg. bid-ask size
Shares at ask/bid
Off exchange
Main News & Impact Reports
6/26
Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-502 Topical in Patients with Alopecia Areata Did Not Meet Endpoints
-52.1%
7/30
Glancy Prongay & Murray LLP Files Securities Class Action on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS)
-39.0%
2/25
Form 10-K Aclaris Therapeutics, For: Dec 31
-22.2%
8/8
Form 10-Q Aclaris Therapeutics, For: Jun 30
-13.5%
9/25
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NASDAQ: ACRS) and Encourages Aclaris Investors to Contact the Firm
-11.7%
11/21
Form 8-K Aclaris Therapeutics, For: Nov 21
-11.2%
3/31
Form 8-K Aclaris Therapeutics, For: Mar 30
-11.1%
9/17
Aclaris Therapeutics to Hold R&D Day
-10.9%
3/6
Form SC 13G Aclaris Therapeutics, Filed by: Samsara BioCapital, L.P.
-10.8%
5/8
Form 10-Q Aclaris Therapeutics, For: Mar 31
-10.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Register